Metastatic breast cancer confined to the skeletal system. An indolent disease

Michael M. Sherry, F. Anthony Greco, David H. Johnson, John D. Hainsworth

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

The records of 86 patients with metastatic breast cancer confined to the skeletal system were retrospectively reviewed to evaluate the clinical impression that this subset of patients with metastatic breast cancer has a favorable prognosis. The median survival for this group of patients was 48 months, compared with a median survival of 17 months in patients with breast cancer metastatic to other sites (p <0.01). Systemic treatment with either hormonal therapy or chemotherapy was highly effective in these patients; 56 of 64 (87 percent) showed response to the first hormonal therapy received (median, 10 months; range, four to 54 months), and 43 of 46 (93 percent) showed response to initial chemotherapy (median, 11 months; range, six to 22 months). Most patients received several therapeutic modalities sequentially; sequential responses to hormonal therapy were frequent. Orthopedic complications were common (pathologic fracture in 18; epidural spinal cord compression in 13) and occurred a median of 24 months after documentation of bone metastasis. Prolonged survival was common after these complications (median, 18 months; range, two to 48 months). The presence of metastatic disease at the time of diagnosis and premenopausal status were not adverse prognostic factors. Metastases often remained localized to the skeleton; however, appearance of extraskeletal metastasis was associated with short subsequent survival (median, nine months). Metastatic breast cancer confined to the skeletal system is a common entity that can be defined clinically, is highly responsive to treatment, and is frequently associated with prolonged survival.

Original languageEnglish (US)
Pages (from-to)381-386
Number of pages6
JournalThe American journal of medicine
Volume81
Issue number3
DOIs
StatePublished - 1986

Fingerprint

Breast Neoplasms
Survival
Neoplasm Metastasis
Therapeutics
Drug Therapy
Spontaneous Fractures
Spinal Cord Compression
Skeleton
Documentation
Orthopedics
Bone and Bones

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Metastatic breast cancer confined to the skeletal system. An indolent disease. / Sherry, Michael M.; Greco, F. Anthony; Johnson, David H.; Hainsworth, John D.

In: The American journal of medicine, Vol. 81, No. 3, 1986, p. 381-386.

Research output: Contribution to journalArticle

Sherry, Michael M. ; Greco, F. Anthony ; Johnson, David H. ; Hainsworth, John D. / Metastatic breast cancer confined to the skeletal system. An indolent disease. In: The American journal of medicine. 1986 ; Vol. 81, No. 3. pp. 381-386.
@article{90cbfafd1fde469db0c68321b38929c1,
title = "Metastatic breast cancer confined to the skeletal system. An indolent disease",
abstract = "The records of 86 patients with metastatic breast cancer confined to the skeletal system were retrospectively reviewed to evaluate the clinical impression that this subset of patients with metastatic breast cancer has a favorable prognosis. The median survival for this group of patients was 48 months, compared with a median survival of 17 months in patients with breast cancer metastatic to other sites (p <0.01). Systemic treatment with either hormonal therapy or chemotherapy was highly effective in these patients; 56 of 64 (87 percent) showed response to the first hormonal therapy received (median, 10 months; range, four to 54 months), and 43 of 46 (93 percent) showed response to initial chemotherapy (median, 11 months; range, six to 22 months). Most patients received several therapeutic modalities sequentially; sequential responses to hormonal therapy were frequent. Orthopedic complications were common (pathologic fracture in 18; epidural spinal cord compression in 13) and occurred a median of 24 months after documentation of bone metastasis. Prolonged survival was common after these complications (median, 18 months; range, two to 48 months). The presence of metastatic disease at the time of diagnosis and premenopausal status were not adverse prognostic factors. Metastases often remained localized to the skeleton; however, appearance of extraskeletal metastasis was associated with short subsequent survival (median, nine months). Metastatic breast cancer confined to the skeletal system is a common entity that can be defined clinically, is highly responsive to treatment, and is frequently associated with prolonged survival.",
author = "Sherry, {Michael M.} and Greco, {F. Anthony} and Johnson, {David H.} and Hainsworth, {John D.}",
year = "1986",
doi = "10.1016/0002-9343(86)90286-X",
language = "English (US)",
volume = "81",
pages = "381--386",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Metastatic breast cancer confined to the skeletal system. An indolent disease

AU - Sherry, Michael M.

AU - Greco, F. Anthony

AU - Johnson, David H.

AU - Hainsworth, John D.

PY - 1986

Y1 - 1986

N2 - The records of 86 patients with metastatic breast cancer confined to the skeletal system were retrospectively reviewed to evaluate the clinical impression that this subset of patients with metastatic breast cancer has a favorable prognosis. The median survival for this group of patients was 48 months, compared with a median survival of 17 months in patients with breast cancer metastatic to other sites (p <0.01). Systemic treatment with either hormonal therapy or chemotherapy was highly effective in these patients; 56 of 64 (87 percent) showed response to the first hormonal therapy received (median, 10 months; range, four to 54 months), and 43 of 46 (93 percent) showed response to initial chemotherapy (median, 11 months; range, six to 22 months). Most patients received several therapeutic modalities sequentially; sequential responses to hormonal therapy were frequent. Orthopedic complications were common (pathologic fracture in 18; epidural spinal cord compression in 13) and occurred a median of 24 months after documentation of bone metastasis. Prolonged survival was common after these complications (median, 18 months; range, two to 48 months). The presence of metastatic disease at the time of diagnosis and premenopausal status were not adverse prognostic factors. Metastases often remained localized to the skeleton; however, appearance of extraskeletal metastasis was associated with short subsequent survival (median, nine months). Metastatic breast cancer confined to the skeletal system is a common entity that can be defined clinically, is highly responsive to treatment, and is frequently associated with prolonged survival.

AB - The records of 86 patients with metastatic breast cancer confined to the skeletal system were retrospectively reviewed to evaluate the clinical impression that this subset of patients with metastatic breast cancer has a favorable prognosis. The median survival for this group of patients was 48 months, compared with a median survival of 17 months in patients with breast cancer metastatic to other sites (p <0.01). Systemic treatment with either hormonal therapy or chemotherapy was highly effective in these patients; 56 of 64 (87 percent) showed response to the first hormonal therapy received (median, 10 months; range, four to 54 months), and 43 of 46 (93 percent) showed response to initial chemotherapy (median, 11 months; range, six to 22 months). Most patients received several therapeutic modalities sequentially; sequential responses to hormonal therapy were frequent. Orthopedic complications were common (pathologic fracture in 18; epidural spinal cord compression in 13) and occurred a median of 24 months after documentation of bone metastasis. Prolonged survival was common after these complications (median, 18 months; range, two to 48 months). The presence of metastatic disease at the time of diagnosis and premenopausal status were not adverse prognostic factors. Metastases often remained localized to the skeleton; however, appearance of extraskeletal metastasis was associated with short subsequent survival (median, nine months). Metastatic breast cancer confined to the skeletal system is a common entity that can be defined clinically, is highly responsive to treatment, and is frequently associated with prolonged survival.

UR - http://www.scopus.com/inward/record.url?scp=0022535311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022535311&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(86)90286-X

DO - 10.1016/0002-9343(86)90286-X

M3 - Article

C2 - 2428242

AN - SCOPUS:0022535311

VL - 81

SP - 381

EP - 386

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 3

ER -